Ingaron

Ingaron is an immunomodulator with antiviral properties.

[ 1 ], [ 2 ]

Indications Ingarona

It is used for injection in the following disorders:

• prevention of the development of complications of infectious origin in people with granulomatous disease;
• elimination of hepatitis types C, as well as B (chronic form), as well as HIV and pulmonary tuberculosis (combination therapy);
• therapy for oncological pathologies (as an immunomodulator as part of combination therapy);
• elimination of chronic prostatitis (combination therapy);
• therapy for chlamydia of a urogenital nature (combined course);
• treatment of herpes in the shingles or genital form (monotherapy);
• elimination of warts in the anogenital area, as well as prevention of relapse.

Intranasal administration is used for the following disorders:

• kala-azar and rubber ulcer (supportive);
• leprosy;
• an infection of mycobacterial origin in people with a negative HIV test in the absence of results from conservative therapy;
• psoriasis;
• atopic dermatitis and eczema;
• rheumatoid arthritis;
• Hodgkin's lymphoma (as part of antibiotic therapy).

[ 3 ]

Release form

It is released in the form of a lyophilisate for the preparation of a solution, in vials with a capacity of 100,000, 200,000, and 500,000 IU of γ-interferon.

Pharmacodynamics

The recombinant form of human γ-interferon includes 144 amino acid elements. The molecular weight is 16.8 kDa. The substance is obtained by microbiological biosynthesis carried out inside the E. coli strain and then purified using column chromatography.

G-interferon is an important proinflammatory cytokine produced by T-killers, CD4 Th1, and CD8 suppressor cells. Monocytes, T-killers, and also neutrophils and cytotoxic T-lymphocytes have receptors for γ-interferon, which in turn promotes the activation of cytokine production, as well as certain types of radicals found inside these cells, which ultimately causes the death of viruses.

The drug activates the binding of proteins that appear in acute inflammation, and also stimulates the process of gene expression within the complementary system. At the same time, Ingaron blocks the processes of viral replication in the area of RNA with DNA, biological binding of viral proteins, and in addition, the assembly of viral elements. In addition, it inhibits the production of β-TGF, which is responsible for the development of pulmonary and liver fibrosis.

Dosing and administration

The drug is administered subcutaneously or intramuscularly. The lyophilisate must be dissolved in water (2 ml). The doses are selected individually.

When treating hepatitis type B or C, as well as tuberculosis or HIV infection, an adult is given an average of 500,000 IU of the drug per day. The procedure is performed daily or every other day. The treatment cycle lasts for 1-3 months. A repeat course is allowed after a 2-month interval.

To prevent the development of complications of infectious origin in people with granulomatous disease, it is necessary to use a dose that averages 500,000 IU. The drug is administered daily or with 1-day intervals. The cycle often consists of 5-15 injections. The therapy can be extended or repeated after 10-14 days.

When treating oncological pathologies, the daily dose is 500,000 IU. The substance should be administered daily or at intervals of 1 day. Certain oncological diseases are treated using a combination of Ingaron and Refnot - drugs that together have a cytotoxic effect, which potentiates the activity of recombinant γ-interferon by 100-1000 times.

When eliminating an infectious process of herpesvirus origin developing in the genital area, shingles or urogenital chlamydia, daily doses of 500,000 IU are used. The substance is administered daily or at intervals of 1 day. The treatment cycle for such diseases consists of 5 injections.

When treating chronic prostatitis, the daily dose is 100,000 IU. The medication is administered daily or with 1-day intervals. The therapeutic cycle consists of 10 injections.

During the treatment of warts located in the anogenital area, the daily injection size is 100,000 IU. The medicine should be administered daily or every other day (if the procedures are performed after cryodestruction, a one-day interval must be maintained). The treatment cycle includes 5 injection procedures.

[ 4 ]

Use Ingarona during pregnancy

It is prohibited to prescribe Ingaron to pregnant and lactating women.

Contraindications

Main contraindications:

• the presence of hypersensitivity to γ-interferon or other components of the drug;
• multiple sclerosis;
• disorders of an autoimmune nature;
• diabetes mellitus.

Side effects Ingarona

The use of the medication may cause local side effects: hyperemia and pain at the injection site.

Overdose

When using large doses (above 1 million IU) of the drug, the patient experiences headaches, arthralgia, a feeling of weakness and an increase in temperature.

To relieve these symptoms, paracetamol should be used.

Storage conditions

Ingaron must be stored in a dry, dark place, out of reach of children. Temperature indicators are within 2-10°C. It is prohibited to freeze the drug.

Shelf life

Ingaron can be used for 2 years from the date of release of the drug.

Application for children

Not for use in children under seven years of age.

Analogues

The following drugs are analogs of the medication: Viferon, Avonex and Grippferon with Inferon, as well as Infagel, Extavia and Betaferon.

[ 5 ], [ 6 ], [ 7 ]

Reviews

Ingaron receives many good reviews, most patients are completely satisfied with the effect of the drug. No one writes about the development of side effects.